InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
1.170
-0.070 (-5.65%)
At close: Nov 13, 2026, 4:00 PM EST
1.140
-0.030 (-2.56%)
After-hours: Nov 13, 2026, 7:30 PM EST
← View all transcripts

3rd Annual Guggenheim Healthcare Innovation Conference

Nov 10, 2026

Summary

Izicopan’s development is centered on renal disease, led by ANCA vasculitis, with additional IgAN, RPGN and aHUS studies planned. Current funding is expected to extend through 2029.

Yatin Suneja
Analyst, Guggenheim

Okay. Good morning, everyone. Welcome to Guggenheim's 3rd Annual Healthcare Innovation Conference. My name is Yatin Suneja, one of the senior biotech analysts here at the firm. It is my pleasure to welcome our next presenting company, InflaRx. We have executives here from the team. We have CEO and founder Niels Riedemann. We have Chief Financial Officer Thomas Taapken, and we also have here with us VP and Head of IR, Jan Medina. Gentlemen, thank you so much for your time. Niels, why don't you make some opening comments? You just hosted a capital market day, provided a lot of update. Perhaps maybe touch a little bit on the key highlights, and then we'll go a little bit more into the depth of the discussion after you make some comments.

Niels Riedemann
CEO and Founder, InflaRx

Yes, absolutely. Happy to do so. First of all, thanks for inviting us, Yatin. Always a pleasure to be here. We just hosted a capital markets day. We are very excited about moving our molecule, izicopan, an oral C5aR inhibitor, which we believe has best-in-class potential into the renal space, particularly in ANCA vasculitis and beyond. We have starting trials here in ANCA vasculitis, a larger one that will be placebo-controlled. Maybe we talk about that a bit more in detail. That's really designed to show efficacy of the molecule on top of standard of care, and also designed to hone in on a signal, particularly on the renal signal. We will kick this off as soon as possible. It's in the making, and it's been informed by initial interactions with the regulators here in this country, with the FDA.

At the same time, we're trying to kick off another study in ANCA vasculitis, which is really more proving the point that you can rapidly replace or completely replace corticosteroids in this disease, which remains one of the key high unmet medical needs. Patients, likewise, as also physicians that we speak to, really mention that that was one of the key advantages the current molecule of avacopan, the approved molecule in this country, has been delivered to patients. We're excited about that because we don't want to drop the ball on this particular aspect. We're getting inbounds from vasculitis foundations in Europe, in the U.S., and elsewhere, really showcasing that this is meaningful to patients.

So, this is also a bit meaningful because we're running with our molecule, and our partner in China, Staidson, is running with the antibody that targets the ligand C5a, is running a phase III with a complete replacement strategy. It's the first trial ever to show that you can replace corticosteroids completely. It's designed for non-inferiority, and it's been informed by discussions with the Chinese regulators that agreed on a non-inferiority design for approval. That's exciting, those data coming in 2028. The open-label data will also, first data coming in in 2028. That would be a very important signal for us. We're also excited beyond. We have a starting study in aHUS. This will be a small study.

It's really with a key center that is a referral center for this disease and has ample knowledge on the complement pathways and really is interested in this trial that we believe really has the potential for a true paradigm shift in the field, and here's why. A lot of people believe that because the drugs like eculizumab, ravulizumab, were the first approvals in this field, had such success that there must be a MAC component, a membrane attack complex component, which, as you know, our drug doesn't touch. We have evidence from research, and others have gathered evidence as well, that the key driver of this disease that evokes this thrombotic microangiopathy, the endothelial damage, is actually likely to be driven by C5a, C5aR. So we're trying to see whether that can be done. If so, it could introduce a true paradigm shift.

People would see that this pathway is very meaningful. Plus, keep in mind, we don't vaccinate patients. We don't see a much higher infection rate with the ligand antibody where we have ample experience, even long-term dosing. That could be huge advantages. At the same time, it's an oral, so that's also for the field important. Even though very small, we may have first patient data to be reported already in 2027. We believe this is interesting also to be mentioning that this is an open-label trial, but this is also open-label situations for approval. So really very rare, very interesting, high-price drug disease area with still unmet need, and the pathway could go into an open-label approval trial later if that works.

Yatin Suneja
Analyst, Guggenheim

Got it.

Niels Riedemann
CEO and Founder, InflaRx

Last but not least, a basket study in IgAN and IgAN RPGN, really to increase probability of success, to show the drug is active in this disease. This will be an open-label study. We will have data coming there already in 2028, initial data, and we think that will further the interest in this molecule in the broader renal space. We also may add another indication. We haven't disclosed that yet, but we're finalizing work on that as well.

Yatin Suneja
Analyst, Guggenheim

Got it. At a high level, what is the development? I mean, it seems like the development strategy is to basically go as broad and capture all of the renal indication that is possible. Would you go beyond the renal areas, or that sort of is the key focus right now?

Niels Riedemann
CEO and Founder, InflaRx

This is the key focus right now. We have very strong conviction that this molecule is active in other areas in the broader I&I space, like in Hidradenitis suppurativa, where we had first data, or even in the space like CSU, which still, these are still chronic spontaneous urticaria, which are still disease areas of unmet need, I would say. There's still improvements to be done. But we focus on renal. The strategy really is to deliver as fast as we can and attempt to market with the C5aR in ANCA vasculitis. That's the key focus because that's where the value is. We are still in discussions with regulators. We're considering path where we can expedite the path to a registrational study.

Our entire strategy is geared towards being as fast as possible, but at the same time, you cannot shortcut certain requirements that the regulators just have.

Yatin Suneja
Analyst, Guggenheim

Sure, I understand. Let's maybe remind our audience the properties of izicopan. How is that differentiated versus avacopan and what you have seen at preclinical level, then healthy volunteer level, then at clinical level?

Niels Riedemann
CEO and Founder, InflaRx

So the original idea to design this, and our team, Ren Guo, the other founder, our CSO, and his team worked for years on this, was the interesting part that ChemoCentryx back then had found a binding site, an allosteric binding site that seemed to be delivering a very potent blocking of the molecule. We thought that there's a real opportunity because we saw the human data. So while in vitro this molecule is very potent, we saw this opportunity to have a much better PK.

Yatin Suneja
Analyst, Guggenheim

Yeah

Niels Riedemann
CEO and Founder, InflaRx

And a better formulation. So originally, we started all the work to say, "We want to make use of the knowledge, but we want to design a better molecule that reaches fast and higher PK," because we believe that, A, in many of the diseases, it's important that your drug is fast-acting, and B, with having a higher coverage of the signal right away, we believe it will translate into more efficacy. In head-to-head preclinical studies, inflammatory studies, we've already shown almost a doubling of efficacy at the exact same dose, so there's evidence that that may be playing out in humans as well. We then learned that by working on this and introducing this trifluoromethyl group, we also seem to have a much better safety.

Yatin Suneja
Analyst, Guggenheim

Yeah

Niels Riedemann
CEO and Founder, InflaRx

Situation because we don't block a very important liver detoxifying enzyme apparatus called CYP3A4/5, which is usually a pathway that metabolizes a lot of drugs and also can cause drug-drug interaction problems. So really, we're differentiated on the speed of onset, on the overall delivery of blocking activity of the drug. We've shown that in assays. We believe we have an advantage in safety.

Yatin Suneja
Analyst, Guggenheim

Yeah

Niels Riedemann
CEO and Founder, InflaRx

On numerous levels. We are also a much more stable drug when it comes to metabolite formation. Last but not least, we haven't talked about that we also have a convenience angle. We pack 30 mg drug strength per capsule. We may have less capsule intake or even go to QD dosing, which is informed by modeling. So really, we created a molecule that's differentiated on every level that may count for patients, and so we're really excited to move this forward.

Yatin Suneja
Analyst, Guggenheim

Got it. Let's maybe go through all of the programs that you have recently highlighted that you're going to be initiating on. Maybe we'll start with AAV, with renal. Can you maybe just walk us through the study design, what feedback has been incorporated with which agency? Is EMA, FDA both involved, or you have feedback from them?

Niels Riedemann
CEO and Founder, InflaRx

Yes. This current, the first trial that we're now starting is the placebo-controlled trial, which is double-blinded and will be run internationally, that's been informed by initial in-depth interactions with the U.S. FDA. It will be a study where we're studying two drugs next to placebo on top of standard of care. We will apply a corticosteroid tapering scheme that is on the lower end, but known and standard in all countries. We've designed this study to show, to give us the maximum chance of an efficacy signal. That is by, A, we're honing in on the renal vasculitis subpopulation, which is about 70%-80% of all patients have renal involvement. We're also allowing very sick renal patients informed by our studies in China with our collaborator.

Then, thirdly, we have created a study where we have a very rapid enrollment, so within days, you should be able to enroll the patient in the study. Why is that? Because, as I mentioned before, we have a very fast-acting drug, and we believe every day you have the C5aR signal covered at the front end of a major flare or new onset, which are life-threatening-

Yatin Suneja
Analyst, Guggenheim

Yeah

Niels Riedemann
CEO and Founder, InflaRx

may preserve organ function, nephron function, kidney function. We're really focusing on the signal of faster kidney recovery, proteinuria, hematuria, and better kidney function. That's the study that is now starting, and designed to give us the maximum opportunity to show an efficacy signal.

Yatin Suneja
Analyst, Guggenheim

Got it. What would be the endpoint, let's say, for an FDA registration study that you would be conducting once you establish a proof of concept?

Niels Riedemann
CEO and Founder, InflaRx

That's an interesting question, but we can't fully answer that yet. But we can answer it in one way that we have been having very good discussions with the FDA on additional efficacy endpoints that they're open to. We haven't fixed one yet on purpose, even though we discussed concretely a few. The openness that we saw to also consider other endpoints from the agency is really welcomed by us because obviously there was one endpoint that everybody looks at for safety reasons, but also for certain efficacy reasons, which is this BVAS score. That's not an easy score. It has certain shortcomings. We can't answer that question yet fully. I would say the positive news is that there's openness to other efficacy signals and the encouragement that we come back with data on some of the endpoints we've discussed.

Yatin Suneja
Analyst, Guggenheim

Got it.

Niels Riedemann
CEO and Founder, InflaRx

To then fix it.

Yatin Suneja
Analyst, Guggenheim

In this study, what standard of care is allowed? I think I noticed you are only allowing RITUXAN, but cyclophosphamide and mycophenolate might not be allowed.

Niels Riedemann
CEO and Founder, InflaRx

Yes. In this study, we fix it to rituximab to really have the best comparability between treatment arms, and we fix the GC standard tapering scheme that is usually used on the lower end, but still it is the worldwide accepted scheme.

Yatin Suneja
Analyst, Guggenheim

Got it. Then, I think the feedback that we got from investor was that, like, there was some expectations of maybe having a more of a streamline or more accelerated development path, and you just mentioned that you are still working on that. Maybe talk about that, the need for phase II before you do the seamless study or you do a phase III.

Niels Riedemann
CEO and Founder, InflaRx

You know, I think the FDA has been, and that is also public from the records of the approval of back then avacopan, has been very consistent in saying they need a superiority efficacy signal for approval, even though we all know rituximab was approved on non- inferiority signal. So that is a very consistent voicing that the agency has done in their interactions. At the same time, that is also visible from the approval package of avacopan. They were open to suggesting you could choose this, you could choose that around BVAS and now maybe beyond. So there is a need to bring phase II data to fix that, but there is openness and not a situation where they demand a signal on one endpoint only, which is really the good news for us, but we have prepared that well.

We have a few concrete ones that we discussed, and we will bring them and look at the ones we would like to choose and fix them then for phase III. We are working on an expeditious path to approval. Yes, there is also our wish to do that as fast as possible. We are assessing a few ways how we can expedite the path to a registrational study. Our strategy is there is a clear need for the FDA to see data to fix it, so you can't just say, "I'll do a phase III without having fixed it." That's not possible. But at the same time, we see a certain chance to go in and have these discussions as early as reasonably possible with data from the trial.

The advantage could be that we don't need such a large phase III trial anymore because we designed the phase II trial well. It can support a registration later, and the phase III trial could then be more concise in being in need of less patient numbers. We can make up some time with that, we believe.

Yatin Suneja
Analyst, Guggenheim

Got it. For this study, what endpoint should we be focusing on, and how would you characterize a success? What exactly would you like to see for you to give confidence to move into phase III or in next steps?

Niels Riedemann
CEO and Founder, InflaRx

The one endpoint we definitely want to see a big signal on earlier proteinuria reduction. That is already there in other studies, also with our own, like, ligand binding antibody in other studies. That would give us confidence that the drug is there, it's active, and it shows some differentiation. It's a signal that can be seen even in very small data sets. Beyond that, we want to see a signal on function, eGFR, we mentioned publicly, and also on other damage signals like hematuria. We have also incorporated composite endpoints that we discussed. We haven't made them yet public, but some of them may be, if you will, something like a time to renal recovery.

or a time to renal remission. The reason why we're considering them is because obviously this is an acute kidney injury moving into a chronic kidney problem in this disease, so it's a bit different from IgAN, for example, where you have a decline. Time to recovery is very important. There's evidence that this is principally important, and that may give you even more power to not having to do a very large study, which in a rare disease is always a challenge. For that matter, we talked about eGFR could be a base case, but we see some upside in combining signals.

Yatin Suneja
Analyst, Guggenheim

Got it. Have you established a data timeframe for this or just the enrollment timeframe you've said? What have you said?

Niels Riedemann
CEO and Founder, InflaRx

Yes, the enrollment timeframe we currently envision is 18 months. Also there, we're working on expediting this because for us, as always voiced, one important angle for speed of enrollment will be conducting the study also in China. We're making good progress towards that, so that could meaningfully impact enrollment speed in all the trials we're doing, even though we're not just doing them in China. We're doing them in Europe, maybe in U.S., depending on the-

Yatin Suneja
Analyst, Guggenheim

Got it. Got it. The next study, which is the open-label study, maybe talk about that, because I think you have relapsing AAV patient. Who are these patient? What type of patient, different subgroups that you're enrolling in the open-label study?

Niels Riedemann
CEO and Founder, InflaRx

Yeah, good point. These are all all-comer patients that are in need for remission induction. That means they have some level of organ affected.

That is the definition of major flare or major onset. They need to be in need of, like, fulfill the need of remission induction. That being said, they do not have to be renal. They can be. They do not have to be very sick, but they can be.

Yatin Suneja
Analyst, Guggenheim

Yeah.

Niels Riedemann
CEO and Founder, InflaRx

The reason for that is, you know, there is good evidence where the standard of care would take you in terms of remission at week 16 and 24. So you have a good comparator to say, "Is this safe to rapidly reduce or completely replace corticosteroids?

Yatin Suneja
Analyst, Guggenheim

Okay.

Niels Riedemann
CEO and Founder, InflaRx

It is not in competition with the other trial really, but we will gather more data, and we want to prove the point. I mentioned the inbounds we get and the importance for patients. We did an external research lately that also showed that that would further the enthusiasm around C5aR inhibition. Generally, people have accepted that you can reduce corticosteroids with that. It is already in the guidelines you can consider, even though it was never in the label of avacopan. But any more data that support this would be seen as very positive.

Yatin Suneja
Analyst, Guggenheim

Got it. So for AAV, at least to us, it seems like it's just a matter of time. You just have to execute the studies because there is already clinical proof of concept with avacopan. Maybe talk a little bit about IgAN and the RPGN subtype that you're going after. What have we seen with other complement approaches? Maybe also what we have seen with avacopan, why you're going there.

Niels Riedemann
CEO and Founder, InflaRx

Yeah. Good point. So I start with IgAN first and want to carve out the RPGN a little bit at the end. So there's very good evidence complement inhibitors are on the path, already approved in this situation, upstream complement inhibitors. And they generally produce the signal that which has been used for accelerated approval, the proteinuria signal, proteinuria reduction signal, by roughly, let's say, 38, 40% to 50%, which is interesting because if you average the placebo data, they are averaging around zero.

Yatin Suneja
Analyst, Guggenheim

Yeah.

Niels Riedemann
CEO and Founder, InflaRx

So there's a very good comp. So if you have a signal that falls in that range, you can be reasonably sure your drug is active. Now, this is just the first stage. We know IgAN is a very competitive space, so we're using it just to show that the drug can do it and to prove that we can maybe move into other IgAN-related, like RPGN, higher unmet needs. I do want to flag those two things. It's an oral, and it doesn't require vaccination, and it works very fast. Now, with the anti-APRILs, and rabuffs coming, we know, and being on the path or even already approved, we know that they very likely will become standard of care.

But for all we understand, there's always going to be a need of combination, and there's such a broad variety of patients that may or may not respond that you always need different therapies. So our intel and our discussion with some of the key KOLs in this space said, "Look, if you're really oral, if you don't need vaccination, if you act fast, that could be an ideal bridge or combination." So there's interest. That's what I'm trying to say, and we have scouted very carefully whether we can conduct this initial study or not. Coming to IgAN RPGN, that's a typical space that is usually excluded from the trials. It's only about 5%, so pretty rare. But if you think about, for example, China, where we looked at that, there's about 4.5 million IgAN patients, so 5% of that is still very meaningful for what we learned.

These studies could be conducted there. Probably not easy to conduct a study there. But if you had any signal to show you can stabilize the renal function in this rapidly progressive part of the disease that usually has a very bad outlook, that could already excite physicians and could actually lend a different angle to how important this pathway is. As I mentioned, we're considering another disease that we haven't made public yet, but really to showcase in the IgAN family and beyond that in these chronic renal diseases, the drug could be making a big impact with the key advantages I mentioned.

Yatin Suneja
Analyst, Guggenheim

Yeah. For these, are these two separate studies, the IgAN and the IgAN with RPGN? When are they going to start, and what is the expectation for the data?

Niels Riedemann
CEO and Founder, InflaRx

We're already working on the protocol. We're already assessing sites. We will start them in parallel with the other studies as soon as reasonably possible.

Yatin Suneja
Analyst, Guggenheim

Got it.

Niels Riedemann
CEO and Founder, InflaRx

Really, like early next year, we're gearing up for rolling this out.

Yatin Suneja
Analyst, Guggenheim

Got it. Maybe then, finally on the aHUS program, tell us a little bit about that, what piqued the interest in that IIT study, and have we seen anything from avacopan in aHUS?

Niels Riedemann
CEO and Founder, InflaRx

I'm not aware of anything with avacopan in aHUS patients, but what we have is ex vivo data with avacopan, and we did the same study ex vivo with the expert group. I think they did it with an expert group in Italy. What you do there is, you have this endothelial cell layer cultured, and this is an assay where you have blood or serum flow over it. If you do that with serum from aHUS patients, this endothelial layer gets either disturbed and you see clotting and you see injury or not. In this model, they clearly pointed that this injury from this aHUS patient's plasma comes from C5aR, not from MAC.

You can elegantly block it with avacopan, with our drug. If you take kidney biopsies from patients with aHUS, what you do see is MAC staining, so C5b-9 staining. A lot of people think that, oh, that's, like when you see the staining, that must have an implication. I am not so sure about that. We see staining of C3d, C3. Whenever complement is activated, you have staining of these products all over the place. Doesn't mean they cause damage themselves to the Because unless you're a PNH patient, we are all protected from MAC damage. Even if you stain, if this attaches to the cell, it shouldn't mean that your cell is damaged. Again, we are very excited about this first look. It's a bit, I would say it's the first proof that this could work, but there's an endpoint called TMA response.

Yatin Suneja
Analyst, Guggenheim

Yeah.

Niels Riedemann
CEO and Founder, InflaRx

That is the primary endpoint for approval. That means you have to normalize your platelets, you normalize a lysis marker called LDH, and you want to see a 25% drop in creatinine. That together is a very simple marker. It is used for approval in open-label studies in this disease. If you have patients with a true aHUS, complement-mediated aHUS, and you have responders, you know the drug works.

Yatin Suneja
Analyst, Guggenheim

Got it.

Niels Riedemann
CEO and Founder, InflaRx

Yeah.

Yatin Suneja
Analyst, Guggenheim

Very good. Maybe just one question then on avacopan, which we did not touch earlier. What is the status of the drug, let us say, in Europe and the U.S.? What is the feedback you are getting from physicians after all the safety updates?

Niels Riedemann
CEO and Founder, InflaRx

In Europe and U.K., it's pulled. In Japan, there's controversy going on. In this country, it's still available on the market. We don't know where the FDA sits with their decision. We will have to see. The question is, will they grant a hearing? They have asked Amgen to pull the drug. Amgen has said, "No, we don't want to do that." So right now, they have requested at least to get a hearing, and we haven't heard about whether they grant a hearing. As far as we understand, there's no legal basis of when or if they have to respond. I think the interesting political situation is that in Europe, basically, the agency just said, "You didn't" I'm translating them, my understanding.

Basically said, in other words, "This is not a GCP-conformed trial because there was an unblinding, so we're not going to take it as basis to even evaluate further." Pretty simple way of saying, "We can't evaluate it." FDA has been much more differentiated on why they're asking it, but you ask for safety. Safety is important. Our external research shows this. If you had a drug that doesn't carry the risk, it would be absolutely preferred. However, safety in Europe and in U.S., a lot of physicians that treat a lot of these patients say, "We can monitor it. We monitor it tightly, and we feel we have it under control.

Yatin Suneja
Analyst, Guggenheim

Got it. Maybe then final question for Tom. How is the cash runway looks like with all these studies that you are undertaking? How you are funded?

Thomas Taapken
CFO, InflaRx

We gave guidance that with the current funding we have, we're funded through 2029, and that's still pretty much valid. We are planning, especially on the ANCHOR program, that's a big chunk of it, and the other studies, as Niels was alluding to, are a little bit smaller studies that don't create such a big cash drain.

Yatin Suneja
Analyst, Guggenheim

Got it. Very well. Thank you, gentlemen. Appreciate it.

Thomas Taapken
CFO, InflaRx

Thank you.